1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain compounds of the following formula (I) (for convenience, collectively referred to herein as "IP compounds"), which, inter alia, are useful in the treatment of cancer, e.g., canc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Menard Delphine, Niculescu-Duvaz Dan, Marais Richard, Niculescu-Duvaz Ion, Zambon Alfonso, Springer Caroline Joy
Format:	Patent
Sprache:	eng
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	Menard Delphine Niculescu-Duvaz Dan Marais Richard Niculescu-Duvaz Ion Zambon Alfonso Springer Caroline Joy
description	The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain compounds of the following formula (I) (for convenience, collectively referred to herein as "IP compounds"), which, inter alia, are useful in the treatment of cancer, e.g., cancer characterized by (e.g., driven by) mutant RAS ("mutant RAS cancer"). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions in the treatment of cancer, e.g., mutant RAS cancer.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US9820976B2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US9820976B2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US9820976B23</originalsourceid><addsrcrecordid>eNqNTctuAjEQ2wuHCvoPOYKEpW6W5xXUau9tTwihQAZtpGwmyiYS6V_1DxsQH9CLZ-wZ2y_Vb43pEpFCxDnFbCHhO3L3pYXPQf2wRYNsZwUPElebODAWmNboKXYPB98Yct5Amy7rcq1bmN7o4j0s5kucjyXIaOOwLkF8y7NnxxEpkBLKaRHIqkhaXLj3nJweHmrsyASRBhLG3UlQPk-q0VXZgV6fc1yJj_evfQvyfKLBqws5iqfvz-1Gvm3Xq51s_vHyB6_GVks</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy</title><source>esp@cenet</source><creator>Menard Delphine ; Niculescu-Duvaz Dan ; Marais Richard ; Niculescu-Duvaz Ion ; Zambon Alfonso ; Springer Caroline Joy</creator><creatorcontrib>Menard Delphine ; Niculescu-Duvaz Dan ; Marais Richard ; Niculescu-Duvaz Ion ; Zambon Alfonso ; Springer Caroline Joy</creatorcontrib><description>The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain compounds of the following formula (I) (for convenience, collectively referred to herein as "IP compounds"), which, inter alia, are useful in the treatment of cancer, e.g., cancer characterized by (e.g., driven by) mutant RAS ("mutant RAS cancer"). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions in the treatment of cancer, e.g., mutant RAS cancer.</description><language>eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2017</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20171121&DB=EPODOC&CC=US&NR=9820976B2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20171121&DB=EPODOC&CC=US&NR=9820976B2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Menard Delphine</creatorcontrib><creatorcontrib>Niculescu-Duvaz Dan</creatorcontrib><creatorcontrib>Marais Richard</creatorcontrib><creatorcontrib>Niculescu-Duvaz Ion</creatorcontrib><creatorcontrib>Zambon Alfonso</creatorcontrib><creatorcontrib>Springer Caroline Joy</creatorcontrib><title>1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy</title><description>The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain compounds of the following formula (I) (for convenience, collectively referred to herein as "IP compounds"), which, inter alia, are useful in the treatment of cancer, e.g., cancer characterized by (e.g., driven by) mutant RAS ("mutant RAS cancer"). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions in the treatment of cancer, e.g., mutant RAS cancer.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2017</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNTctuAjEQ2wuHCvoPOYKEpW6W5xXUau9tTwihQAZtpGwmyiYS6V_1DxsQH9CLZ-wZ2y_Vb43pEpFCxDnFbCHhO3L3pYXPQf2wRYNsZwUPElebODAWmNboKXYPB98Yct5Amy7rcq1bmN7o4j0s5kucjyXIaOOwLkF8y7NnxxEpkBLKaRHIqkhaXLj3nJweHmrsyASRBhLG3UlQPk-q0VXZgV6fc1yJj_evfQvyfKLBqws5iqfvz-1Gvm3Xq51s_vHyB6_GVks</recordid><startdate>20171121</startdate><enddate>20171121</enddate><creator>Menard Delphine</creator><creator>Niculescu-Duvaz Dan</creator><creator>Marais Richard</creator><creator>Niculescu-Duvaz Ion</creator><creator>Zambon Alfonso</creator><creator>Springer Caroline Joy</creator><scope>EVB</scope></search><sort><creationdate>20171121</creationdate><title>1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy</title><author>Menard Delphine ; Niculescu-Duvaz Dan ; Marais Richard ; Niculescu-Duvaz Ion ; Zambon Alfonso ; Springer Caroline Joy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US9820976B23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2017</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>Menard Delphine</creatorcontrib><creatorcontrib>Niculescu-Duvaz Dan</creatorcontrib><creatorcontrib>Marais Richard</creatorcontrib><creatorcontrib>Niculescu-Duvaz Ion</creatorcontrib><creatorcontrib>Zambon Alfonso</creatorcontrib><creatorcontrib>Springer Caroline Joy</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Menard Delphine</au><au>Niculescu-Duvaz Dan</au><au>Marais Richard</au><au>Niculescu-Duvaz Ion</au><au>Zambon Alfonso</au><au>Springer Caroline Joy</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy</title><date>2017-11-21</date><risdate>2017</risdate><abstract>The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain compounds of the following formula (I) (for convenience, collectively referred to herein as "IP compounds"), which, inter alia, are useful in the treatment of cancer, e.g., cancer characterized by (e.g., driven by) mutant RAS ("mutant RAS cancer"). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions in the treatment of cancer, e.g., mutant RAS cancer.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng
recordid	cdi_epo_espacenet_US9820976B2
source	esp@cenet
subjects	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title	1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T16%3A06%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Menard%20Delphine&rft.date=2017-11-21&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS9820976B2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true